Total Funding
95
97
Total FundingPost-IPO Equity raised
Growth Score
2 pts
Heat Score
33 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
23
Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.
Weiqing Zhou: Co-founder & COO- Fawzi Benzaghou: Chief Medical OfficerPast Role: Ipsen, Senior Vice President and Global Head of Oncology
About the Company
Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced a
novel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach.
Women Founded
